Latest news with #DyadicInternational
Yahoo
02-07-2025
- Business
- Yahoo
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
Reflects the Company's strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms JUPITER, Fla., July 02, 2025--(BUSINESS WIRE)--Dyadic International, Inc. ("Dyadic") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced that, effective in 30 days, it will be doing business as Dyadic Applied BioSolutions, marking a pivotal step in the company's transition from a research-driven organization to a commercially focused enterprise. The new name and revised visual identity reflect Dyadic's strategic emphasis on delivering applied biotechnology solutions through its patented and proprietary C1 and Dapibus™ gene expression platforms. The rebrand underscores Dyadic's focus on commercializing high value, non-therapeutic proteins that it believes are essential to life sciences, food, nutritional, and industrial bioprocessing applications. These proteins avoid the regulatory complexity and high costs associated with therapeutic biologics – enabling faster time to revenue, broader market reach, and long-term supply agreements. Recent significant milestones across both food and nutrition as well as fully funded legacy collaborations, discussed below, underscore Dyadic's strategic shift toward focusing on the commercial execution and market readiness of its C1 and Dapibus™ platforms. "As we evolve from licensing our technology in support of therapeutic and vaccine development into a revenue-focused bioprocessing protein platform business, our C1 and Dapibus™ production platforms remain the engines we expect to drive commercial execution," said Joe Hazelton, President and Chief Operating Officer of Dyadic. "The progress on our second non-animal dairy enzyme program – which recently triggered a $250,000 milestone payment – reflects the tangible outcomes of our new focus on commercialization. This rebranding reflects our top priority to deliver high-value input proteins at commercial scale." In parallel with its internal commercial focus, Dyadic continues to advance legacy collaborations with key global health partners. Dyadic recently achieved milestones in its partnership with the Gates Foundation, resulting in a second installment of $1.5 million in non-dilutive funding from a $3.0 million grant to further develop low-cost monoclonal antibodies (mAbs) for diseases such as malaria and RSV. Dyadic remains on track to commercialize its input proteins in 2025, and we believe Dyadic Applied BioSolutions is positioned to deliver sustained revenue and long-term value growth through its production platforms. About Dyadic Applied BioSolutions Dyadic Applied BioSolutions is a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications across the life sciences, food and nutrition, and industrial biotechnology sectors. These proteins are expected to serve as essential components in bioprocessing, formulation, and product development, enabling innovation without the regulatory complexity and high costs associated with therapeutic biologics. Dyadic's proprietary microbial platforms are built on the industrially proven, highly productive and GRAS-accepted fungal host Thermothelomyces heterothallica. Its lead technology, the C1 Expression System, delivers precision engineered proteins and production strains that have redefined performance, scalability, and economy for life sciences and pharmaceutical applications. Dyadic's Dapibus™ platform is expected to further expand its capabilities into food, nutrition, wellness and industrial applications, offering rapid development and large-scale production of recombinant proteins and other biological inputs. For more information, visit Safe Harbor Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, including those regarding the Company's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, including its strategic rebranding. Forward-looking statements involve many risks, uncertainties or other factors beyond the Company's control. These factors include, but are not limited to, the Company's history of net losses; the Company's capital needs; market and regulatory acceptance of the Company's microbial protein production platforms and other technologies, failure to commercialize the Company's microbial protein production platforms or the Company's other technologies; competition, including from alternative technologies; the results of nonclinical studies and clinical trials; changes in global economic and financial conditions; the Company's reliance on information technology; the Company's dependence on third parties; government regulations and environmental, social and governance issues; and intellectual property risks. For a more complete description of the risks that could cause the Company's actual results to differ from the Company's current expectations, please see the section entitled "Risk Factors" in the Company's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), as such factors may be updated from time to time in the Company's periodic filings with the SEC, which are accessible on the SEC's website and at All forward-looking statements speak only as of the date made, and except as required by applicable law, the Company assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in the Company's expectations. View source version on Contacts Dyadic Applied BioSolutionsPing W. RawsonChief Financial OfficerPhone: (561) 743-8333Email: ir@
Yahoo
16-05-2025
- Business
- Yahoo
Dyadic International First Quarter 2025 Earnings: US$0.068 loss per share (vs US$0.07 loss in 1Q 2024)
Revenue: US$393.6k (up 18% from 1Q 2024). Net loss: US$2.03m (flat on 1Q 2024). US$0.068 loss per share. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 7.9% from a week ago. You still need to take note of risks, for example - Dyadic International has 4 warning signs (and 1 which is concerning) we think you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
16-05-2025
- Business
- Yahoo
Dyadic International First Quarter 2025 Earnings: US$0.068 loss per share (vs US$0.07 loss in 1Q 2024)
Revenue: US$393.6k (up 18% from 1Q 2024). Net loss: US$2.03m (flat on 1Q 2024). US$0.068 loss per share. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 7.9% from a week ago. You still need to take note of risks, for example - Dyadic International has 4 warning signs (and 1 which is concerning) we think you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
16-04-2025
- Business
- Yahoo
Dyadic to Present at World Vaccine Congress
JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ('Dyadic', 'we', 'us', 'our', or the 'Company') (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C. World Vaccine Congress | Washington, 22–24, 2025Presentation: Wednesday, April 23, 2025 | 12:40 PM–1:10 PMTrack: Influenza & Respiratory | Room 202ATopic: C1 Platform: The Urgent Need for Smarter Biomanufacturing – A Call to Action on Avian Influenza (H5N1) & Future Pandemics During the presentation, Mr. Emalfarb will provide an overview of recent preclinical research utilizing Dyadic's proprietary C1 expression platform, including data related to the production of non-mRNA antigens and reagents for vaccine production. 'We are excited to share the latest pre-clinical data from multiple studies demonstrating that Dyadic's proprietary C1 platform enables the production of non-mRNA antigens that elicit high neutralizing antibodies,' said Mr. Emalfarb. 'Leveraging our C1 platform, we aim to enable rapid, cost-effective production of antigens, reagents and cell culture media products to address significant global health challenges, including avian influenza and future pandemics, through scalable and efficient biomanufacturing to meet the growing demand for rapid-response vaccines and therapeutics, paving the way for a more resilient global health infrastructure.' Dyadic's management team will be available for meetings throughout the conference. To schedule a meeting, please contact assistant@ or visit booth #654 during the event. About Dyadic International, Inc. Dyadic International, Inc., is a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. Dyadic's microbial gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead platform, the C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and potentially improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness. Dyadic is focusing on leveraging its microbial platform technologies for itself and its collaborators in a wide range of applications, including human and animal vaccines, therapeutics, food, nutrition, wellness, and internal biological products. For more information about Dyadic International, visit Safe Harbor Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled 'Risk Factors' in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at Contact:Dyadic International, W. RawsonChief Financial OfficerPhone: (561) 743-8333Email: ir@
Yahoo
06-03-2025
- Business
- Yahoo
Dyadic to Attend Multiple Industry Events in March
JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ('Dyadic', 'we', 'us', 'our', or the 'Company') (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced its management's participation in several prominent industry events worldwide. World AGRI-Tech Innovation Summit March 11-12, 2025San Francisco, CA Future Food-TechMarch 13–14, 2025San Francisco, CADyadic Booth No: #2 Microbial Engineering III: New Generation of Cell Factory to Meet the Future Challenges and Seize New OpportunitiesMarch 30-April 3, 2025Porto, Portugal Please contact assistant@ if you would like to schedule a meeting with Dyadic management. About Dyadic International, Inc. Dyadic International, Inc., is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. Dyadic's microbial gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead platform, the C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and potentially improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness. Dyadic is focusing on leveraging its microbial platform technologies for itself and its collaborators in a wide range of applications, including human and animal vaccines, therapeutics, food, nutrition, wellness, and internal biological products. For more information about Dyadic International, visit Safe Harbor Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled 'Risk Factors' in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at Contact:Dyadic International, W. RawsonChief Financial OfficerPhone: (561) 743-8333Email: ir@ in to access your portfolio
